Clinical impact of vancomycin-resistant enterococci

J Antimicrob Chemother. 2003 Jun;51 Suppl 3:iii13-21. doi: 10.1093/jac/dkg272.

Abstract

In humans, vancomycin-resistant enterococci (VRE) most commonly result in intestinal colonization, which does not result in symptoms, may persist for a long time and serves as a reservoir for transmission of VRE to other patients. Certain VRE-colonized patients are at risk of infection, including haematology and oncology patients, patients in intensive care units and recipients of solid (especially abdominal) organ transplants. Controlling the spread of VRE colonization and preventing colonized patients from becoming infected are important aims. Ramoplanin is a member of a new class of antimicrobial agents; it may have a role in preventing infection in patients colonized with VRE.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Cross Infection / prevention & control*
  • Cross Infection / transmission
  • Depsipeptides*
  • Enterococcus / classification
  • Enterococcus / drug effects*
  • Enterococcus / genetics
  • Gram-Positive Bacterial Infections / prevention & control*
  • Gram-Positive Bacterial Infections / transmission
  • Humans
  • Infection Control
  • Peptides, Cyclic / therapeutic use*
  • Vancomycin Resistance / genetics*

Substances

  • Anti-Bacterial Agents
  • Depsipeptides
  • Peptides, Cyclic
  • ramoplanin